RecruitingNot ApplicableNCT05934409

Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery

Improved Adipose Tissue Storage of Dietary Fatty Acids as a New Mechanism for the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery


Sponsor

Université de Sherbrooke

Enrollment

40 participants

Start Date

Nov 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and Type 2 Diabetes (T2D) remission after bariatric surgery. All participants will have a bariatric surgery, divided in 2 groups: with or without T2D.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how bariatric (weight loss) surgery rapidly improves liver and heart health by changing how fat is stored in the body. Researchers will compare outcomes in patients with and without type 2 diabetes who undergo bariatric surgery. **You may be eligible if...** - You are aged 18–65 - You have a BMI of 35 kg/m² or above (severely obese) - You have been diagnosed with type 2 diabetes OR you do not have type 2 diabetes - Women must have a negative pregnancy test **You may NOT be eligible if...** - You currently take certain medications (oral contraceptives, fibrates, thiazolidinediones, insulin, or beta-blockers) that affect metabolism and cannot be temporarily stopped - You have overt cardiovascular disease, liver failure, kidney failure, or other uncontrolled medical conditions - You smoke or drink more than 2 alcoholic beverages per day - You have a contraindication to surgery or cannot temporarily stop your diabetes/lipid/blood pressure medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBariatric surgery

Laparoscopic Sleeve Gastrectomy

DRUGNicotinic Acid

Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.


Locations(1)

centre de recherche du CHUS

Sherbrooke, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05934409


Related Trials